In a press release, Pfizer and BioNTech stated, “…results from a Phase 2/3 trial show a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age."
In a press release, Pfizer and BioNTech stated, “…results from a Phase 2/3 trial show a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age."